Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem

Sunghwan Suh; Mi Kyoung Park

doi:10.3803/EnM.2017.32.2.180

Articles

Page Path: HOME > Endocrinol Metab > Volume 32(2); 2017 > Article

Review Article Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem: Sunghwan Suh, Mi Kyoung Park; Endocrinology and Metabolism 2017;32(2):180-189.
DOI: https://doi.org/10.3803/EnM.2017.32.2.180
Published online: May 29, 2017

Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea.

Corresponding author: Mi Kyoung Park. Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, 26 Daesingongwon-ro, Seo-gu, Busan 49201, Korea. Tel: +82-51-240-2815, Fax: +82-51-242-5852, pmk02@dau.ac.kr

• Received: March 12, 2017 • Revised: March 20, 2017 • Accepted: March 27, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

17,940 Views
676 Download
118 Web of Science
125 Crossref
132 Scopus

prev next

Full Article

Download PDF

ABSTRACT
INTRODUCTION
PREVALENCE
PATHOPHYSIOLOGY
CLINICAL COURSE
DEFINITION AND DIAGNOSIS
TREATMENT
NON-PHARMACOLOGIC INTERVENTION
ORAL HYPOGLYCEMIC AGENTS
INSULIN SENSITIZERS
INSULIN SECRETAGOGUES
INCRETIN MIMETICS
INSULIN
MANAGEMENT OF HYPERGLYCEMIA IN PRE-EXISTING DIABETES
PATIENT EDUCATION
CONCLUSIONS
ACKNOWLEDGMENT
Article information
References

ABSTRACT

Glucocorticoids are widely used as potent anti-inflammatory and immunosuppressive drugs to treat a wide range of diseases. However, they are also associated with a number of side effects, including new-onset hyperglycemia in patients without a history of diabetes mellitus (DM) or severely uncontrolled hyperglycemia in patients with known DM. Glucocorticoid-induced diabetes mellitus (GIDM) is a common and potentially harmful problem in clinical practice, affecting almost all medical specialties, but is often difficult to detect in clinical settings. However, scientific evidence is lacking regarding the effects of GIDM, as well as strategies for prevention and treatment. Similarly to nonsteroid-related DM, the principles of early detection and risk factor modification apply. Screening for GIDM should be considered in all patients treated with medium to high doses of glucocorticoids. Challenges in the management of GIDM stem from wide fluctuations in postprandial hyperglycemia and the lack of clearly defined treatment protocols. Together with lifestyle measures, hypoglycemic drugs with insulin-sensitizing effects are indicated. However, insulin therapy is often unavoidable, to the point that insulin can be considered the drug of choice. The treatment of GIDM should take into account the degree and pattern of hyperglycemia, as well as the type, dose, and schedule of glucocorticoid used. Moreover, it is essential to instruct the patient and/or the patient's family about how to perform the necessary adjustments. Prospective studies are needed to answer the remaining questions regarding GIDM.
Keywords: Glucocorticoids; Hyperglycemia; Diabetes mellitus

INTRODUCTION

Glucocorticoids have been shown to be potent anti-inflammatory and immunosuppressive drugs; they started to be used for therapeutic purposes in the mid-20th century, and are currently widely used in the treatment of many diseases [1]. At any point in time, up to 0.9% of the general population may be using cor-ticosteroids, with the highest rate of use (2.5%) seen in individuals 70 to 79 years of age. Moreover, nearly one-quarter of patients may need to use corticosteroids for more than 6 months [2]. Glucocorticoids are extensively used in almost every subspecialty of medicine [3]. Although they are widely prescribed for their anti-inflammatory and immunosuppressive properties, glucocorticoids have a range of common metabolic side effects including hypertension, osteoporosis, and diabetes [2]. Glucocorticoid-induced diabetes mellitus (GIDM) has been recognized as a complication of glucocorticoid use for over 60 years [4]. Glucocorticoids are the drug group most often associated with the onset of hyperglycemia or diabetes mellitus [1]. Glucocorticoids exacerbate hyperglycemia in patients with diabetes mellitus, unmask undiagnosed diabetes mellitus or may precipitate the appearance of GIDM, which is an independent risk factor for other complications associated with the use of these drugs [2]. Furthermore, although it is expected that the blood glucose levels of non-diabetic patients should normalize after discontinuing glucocorticoid use, this does not always happen, and such patients require close monitoring due to the risk of developing diabetes mellitus in the future [5].

The diagnosis and treatment of GIDM are surprisingly undervalued by many health-care professionals, although GIDM results in an increased use of medical care and the development of associated morbidities that affect medical costs and patients' quality of life [2]. Despite the high prevalence of corticosteroid use in clinical practice and the strong association of glucocorticoids with new-onset hyperglycemia, limited information is available regarding the pathophysiology, frequency, and diagnosis of this condition. Similarly, prospective studies assessing the effectiveness of preventive measures taken against this condition and comparing the effectiveness of different treatment schedules are lacking. Therefore, the primary goal of this review article was to highlight the most recent evidence regarding the clinical aspects of GIDM.

PREVALENCE

The incidence of glucocorticoid-induced hyperglycemia has been reported to be 12% [6]. Other studies of the prevalence of GIDM associated with different diseases have reported varying results [7 8 9]. However, the exact prevalence of hyperglycemia secondary to glucocorticoid therapy is not known, making this an unpredictable challenge for general practitioners and endocrinologists alike [5]. Gulliford et al. [10] reported that 2% of incident cases of diabetes were associated with oral glucocorticoids in a primary care population. The prevalence of abnormal glucose metabolism in patients with an organ transplant who undergo glucocorticoid therapy has been reported to be 17% to 32% [11]. GIDM has been reported to have an even greater prevalence among patients treated with glucocorticoids for rheumatoid arthritis [12]. A recent meta-analysis indicated that the rates of glucocorticoid-induced hyperglycemia and diabetes were 32.3% and 18.6%, respectively [13]. The length of time on glucocorticoids, the relative potency of the glucocorticoid and the absolute dose all play a role in the occurrence of GIDM [14]. The odds ratio for presenting with new-onset diabetes after taking glucocorticoids in various studies has been reported to range from 1.36 to 2.31 [10].

It is unlikely that the development of hyperglycemia is related only to the existence of an underlying disease, because abnormalities in glucose metabolism have also been observed in experimental studies with healthy subjects. The incidence of hyperglycemia (defined as blood glucose >200 mg/dL) in hospitalized patients without a known history of diabetes who are treated with corticosteroids is over 50% [7]. Not all patients who use glucocorticoids develop GIDM, suggesting that GIDM occurs only in vulnerable populations. A number of predictors of the onset of GIDM have been identified [1 2 9 15]. These predictors include the dose and duration of glucocorticoid treatment, age, weight, previous glucose intolerance, reduced sensitivity to insulin or impaired insulin secretion stimulated by glucose, a family history of diabetes, or race, as shown in Table 1. Gender does not seem to be a predictor and, conversely, early withdrawal from corticosteroids is a protective factor [1 2 9 15]. Various glucocorticoids differ in their pharmacological properties and duration of action, and can be administered in different schedules depending on the therapeutic indication. These drugs may cause hyperglycemia when administered at supraphysiological doses by any route (topical, oral, inhaled, intramuscular, intravenous, or intra-articular) [10].

PATHOPHYSIOLOGY

The effects of glucocorticoids on glucose homeostasis are complex and not completely understood. Their negative effects are believed to be caused by a variety of factors, including increased insulin resistance, increased glucose intolerance, reduced β-cell mass from β-cell dysfunction, and increased hepatic insulin resistance leading to impaired suppression of hepatic glucose production [16 17]. The metabolic effects of glucocorticoids on glucose metabolism are seen at numerous stages in the insulin-signaling cascade [5]. Prednisolone administration for 7 days in healthy volunteers led to a 50% reduction in insulin sensitivity, as assessed using the insulin clamp methodology [18]. The effect of glucocorticoids on glucose metabolism likely results from the impairment of multiple pathways, including β-cell dysfunction (sensitivity to glucose and ability to release insulin) and insulin resistance in other tissues [3]. Glucocorticoids reduce peripheral glucose uptake at the level of the muscle and adipose tissue [19 20]. Skeletal muscle is primarily responsible for the insulin-mediated capture of postprandial glucose and corticosteroids can induce insulin resistance by interfering directly with various components of the insulin signaling cascade [19 21]. Chronic glucocorticoid overexposure alters body composition, including the expansion of adipose tissue depots in the trunk, and impairs metabolism and insulin action, resulting in hyperglycemia and dyslipidemia [16]. The ability of glucocorticoids to induce adipose tissue lipolysis depends on their concentration, duration of exposure, and the specific adipose tissue depot [16]. The liver plays a major role in the control of glucose metabolism, maintaining fasting euglycemia. Corticosteroids increase endogenous glucose production directly by activating numerous genes involved in the hepatic metabolism of carbohy-drates, leading to increased gluconeogenesis [19 22]. Glucocorticoids also inhibit the production and secretion of insulin from pancreatic β-cells [23 24]. The abilities of glucocorticoids to induce hyperglycemia depend on their dose and the duration of exposure [16 25]. In addition to insulin resistance, inflammatory disease states themselves may induce β-cell dysfunction through indirect mechanisms [11]. The mechanisms of glucocorticoid-induced hyperglycemia are summarized in Table 2.

CLINICAL COURSE

There are several reasons why glucocorticoid-induced hyperglycemia is important in clinical practice. First, it is quite common, and the problems of hyperglycemia itself, which are often severe, may cause hospitalization, prolonged hospital stays, or repeated emergency room visits. Second, glucocorticoids increase the risk of infection due to persistent hyperglycemia, which has a deleterious effect on patients' prognoses. Moreover, the control of transient hyperglycemia in similar situations during hospitalization has been associated with decreased mortality and complication rates [26 27 28]. Most inpatients given glucocorticoids at a dose at least equivalent to 40 mg/day for more than 2 days develop hyperglycemia [11]. It is well known that glucocorticoid therapy may provoke new-onset type 2 diabetes mellitus (T2DM) and invariably worsens hyperglycemia in patients with preexisting diabetes mellitus [10]. Glucocorticoids are a well-known cause of hyperosmolar hyperglycemic nonketotic syndrome [28], which requires admission to the hospital for aggressive hydration and insulin therapy. The tendency for high-risk patients to develop new-onset hyperglycemia is often not anticipated, and outpatients with new-onset GIDM frequently require hospitalization for intravenous hydration and initiation of insulin therapy. In addition, hyperglycemia in hospitalized patients (with or without diabetes) has been associated with poor outcomes regardless of the underlying cause [17]. Inpatient hyperglycemia is known to be associated an increased length of stay and a greater incidence of infections [27]. In addition, sustained glucocorticoid treatment increases the potential for future cardiovascular disease through multiple pathways [11]. Glucocorticoids are administered using different schedules, doses, and methods, and it is possible that the mode of administration (e.g., inhaled, injected, or topical) and dosing regimen may affect the development of hyperglycemia [2]. Knowledge of these hyperglycemia patterns is essential to establish the most appropriate strategy for diagnosis and therapy.

DEFINITION AND DIAGNOSIS

GIDM is defined as an abnormal increase in blood glucose associated with the use of glucocorticoids in a patient with or without a prior history of diabetes mellitus. The diagnosis of GIDM, as well as other types of diabetes, is set according to the criteria established by expert committees [29]. The current criteria for diagnosing diabetes are an 8-hour fasting blood glucose level ≥7.0 mmol/L (126 mg/dL), a 2-hour post-75 g oral glucose tolerance test (OGTT) ≥11.1 mmol/L (200 mg/dL), a hemoglobin A1c (HbA1c) percentage ≥6.5%, or in patients with symptoms of hyperglycemia, a random plasma glucose reading ≥11.1 mmol/L (200 mg/dL) [29].

It is generally thought that glucocorticoids result mainly in an increase in postprandial blood glucose levels [30]. The use of a continuous blood glucose monitor in chronic obstructive pulmonary disease patients treated with prednisolone demonstrated that hyperglycemia predominantly occurred in the afternoon and evening, indicating that this would be the most appropriate time to screen for GIDM as well as the preferable time to implement specific treatments [31]. In patients treated with most glucocorticoids, measuring fasting blood glucose can underestimate glucocorticoid-induced hyperglycemia and diabetes, particularly in intermediate-acting treatments that are administered in single morning doses. However, given the pathophysiology and pattern of glucocorticoid-induced hyperglycemia, it can be inferred that the established criteria [29] provide a low diagnostic sensitivity in most patients with GIDM. For most glucocorticoids, measuring fasting blood glucose can underestimate glucocorticoid-induced hyperglycemia and diabetes, especially in cases of intermediate-acting glucocorticoid treatment with single morning doses [11]. On the contrary, postprandial glycemia after lunch offers the greatest diagnostic sensitivity. Preprandial glycemia at dinner offers less sensitivity, but is easier to standardize [11]. Blood glucose monitoring should be considered for non-diabetic patients who are at high risk of developing GIDM as shown in Table 1 [5]. In addition, an OGTT should also be performed as early as to detect diabetes in those deemed to be at risk [32]. However, the OGTT does not seem suitable for the diagnosis of GIDM because, apart from the difficulties associated with its implementation, it is performed in fasting patients and may underestimate the increase in glucose levels that occurs predominantly in the evening [2]. HbA1c may be a suitable method for diagnosis in patients treated with corticosteroids for >2 months, but it is not useful for patients whose treatment has been initiated more recently. Recently, Japanese scientists developed a detection algorithm for GIDM and suggested that monitoring changes in HbA1c levels is important for detecting GIDM [33]. In patients where HbA1c levels could be unreliable, such as those with hemoglobinopathies, renal failure, or anemia/recent blood transfusion, fructosamine measurements would be a better alternative [5]. In order to appreciate the magnitude of GIDM, one needs to consider that glucocorticoids cause predominantly postprandial hyperglycemia and therefore, using impaired fasting glucose as the sole diagnostic criterion, may underestimate the true incidence of GIDM. Therefore, the most useful criterion for the diagnosis of GIDM in most patients is a glucose level >200 mg/dL at any time of the day [2].

In patients with pre-existing diabetes or risk factors for GIDM, screening should be performed even when low doses of corticosteroids are indicated [2]. However, no glucose monitoring was performed in 24% of patients receiving high-dose glucocorticoid therapy [7]. Failure to appreciate the frequency of hyperglycemia in patients without diabetes is associated with the time course of corticosteroid action with prednisone or prednisolone given once daily [7]. No consensus exists for the optimal screening frequency. Some authors recommend screening with a once- to twice-weekly 2-hour post-lunch capillary blood glucose test in patients who are not known to be diabetic, but who are at a high risk of GIDM [5]. The American Diabetes Association further recommended that glucose monitoring be conducted in patients without known diabetes who receive therapies with a high risk of hyperglycemia, such as parenteral or enteral nutrition, glucocorticoids, immunosuppressive therapy, or octreotide [26]. The Endocrine Society recommended that all patients have blood glucose levels tested on admission, regardless of whether they have a pre-existing diagnosis of diabetes [27]. This approach is believed to be warranted by the opportunity to diagnose new diabetes and to assess glycemic control early course of hospitalization. Gonzalez-Gonzalez et al. [34] reported that, 50% of the time, GIDM occurred between the 2nd and 4th week. Therefore, continued blood glucose monitoring is advisable before meals and at bedtime in patients who exhibit hyperglycemia, and is definitely recommended for those who require anti diabetic medications.

TREATMENT

Efforts to minimize hyperglycemic episodes are beneficial for patients exposed to glucocorticoids. Fluctuations in plasma glucose concentrations have shown an increased risk of cardiovascular mortality [35]. As is the case for diagnosis, no clear evidence exists for the establishment of therapeutic goals in patients with GIDM. From a practical standpoint, we recommend that the treatment of corticosteroid-induced hyperglycemia be considered when the preprandial and postprandial capillary glucose levels are ≥140 and ≥200 mg/dL, respectively. In the case of chronic treatment with glucocorticoids at more or less stable doses, the control goals and the need for drug treatment can be based on the recommended control aims for most patients with diabetes mellitus: preprandial glycemia <130 mg/dL, postprandial glycemia <180 mg/dL, and HbA1c <7% [26 27]. Similarly to the recommendations for T2DM, the introduction of therapeutic measures should be progressive and additive. The selection strategy for hypoglycemic drugs should prioritize those with a mechanism of action that fits with the pathophysiology of the process and the patient's hyperglycemic profile. In the posttransplant setting, as more studies will be conducted with these and other agents, it is essential to focus attention to on drug—drug interactions is essential.

At present, no consensus guidelines exist for the optimal management of hyperglycemia secondary to glucocorticoids, although various opinions have been published by international organizations. There is no evidence to confirm which hypoglycemic drugs and treatment regimens are more effective in achieving adequate glycemic control and lowering complication rates in patients with glucocorticoid-induced hyperglycemia [2]. Therefore, the recommendations proposed in the present review are based on the pathophysiology of the process, the mechanism of action of various hypoglycemic drugs, and few clinical studies. First, it is important to evaluate the degree of pre-existing glucose intolerance, the patient's clinical condition, and the degree of hyperglycemia. Second, it is essential to determine the type, dose, and frequency of administration of the corticosteroid compound. Third, it is necessary to recognize the mechanism of action, pharmacokinetics, and pharmacodynamics of various hypoglycemic drugs. The final relevant aspect of addressing the treatment of GIDM is to differentiate between temporary and indefinite treatment with glucocorticoids. All these aspects condition the selection and schedule of hypoglycemic measures, as well as the goals set in terms of glycemic control. Together with, or after, lifestyle measures, hypoglycemic drugs with insulin-sensitizing effects are indicated. Other oral hypoglycemic drugs or insulin therapy can be considered as the second drug of choice [2]. As second drugs of choice, pioglitazone, sulfonylureas, glinides, dipeptidylpeptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists or insulin therapy can be considered, taking into account their profile of action, tolerance, cost, and risk for hypoglycemia, especially at night [1].

NON-PHARMACOLOGIC INTERVENTION

As with all types of diabetes, the initial steps to improve glycemic control incorporate lifestyle modifications, which include exercise and dietary counseling to provide options that may reduce postprandial hyperglycemia [3].

ORAL HYPOGLYCEMIC AGENTS

Theoretically, of the entire range of oral agents that can be used to treat glucocorticoid-induced or glucocorticoid-exacerbated diabetes, preference should be given to agents that target postprandial hyperglycemia and have a rapid onset of action. The information currently available in the literature suggests that oral agents do not adequately control hyperglycemia in hospitalized patients, and that sliding-scale regimens have resulted in hypoglycemia [17]. For these reasons, the use of oral hypoglycemic drugs is reserved for the treatment of mild glucocorticoid-induced hyperglycemia (glycemia <200 mg/dL) in patients without known diabetes or with diabetes adequately controlled by lifestyle measures or oral hypoglycemic drugs [2]. In the absence of studies comparing different strategies, the choice of the oral hypoglycemic drug should depend on the type and schedule of the corticosteroid and on the potential advantages and disadvantages of oral hypoglycemic drugs.

INSULIN SENSITIZERS

Together or after lifestyle measures, metformin and, in cases of intolerance or contraindication to metformin, pioglitazone are useful and can be considered the first choice in patients who receive chronic treatment with low doses of intermediate-acting glucocorticoids administered in the morning [1]. The characteristics of metformin and pioglitazone that contribute to their selection include their insulin-sensitizing effect, which avoids the risk of hypoglycemia, and the low cost of metformin. The dose and use of these drugs in GIDM does not differ from other clinical settings. Metformin is an attractive option because it enhances insulin sensitivity; thus, preventing metabolic side effects during systemic glucocorticoid therapy [36]. However, many patients treated with glucocorticoids receive treatment for conditions associated with hypoxia and renal insufficiency, which are both at least relative contraindications to the use of metformin because of the increased risk of lactic acidosis. In patients requiring long-term glucocorticoid use, metformin could be a reasonable choice given acceptable renal and liver function. Thiazolidinediones (TZDs) may improve diabetes-related parameters by antagonizing the pathways of glucocorticoid-induced insulin resistance and by reversing the adverse effects of glucocorticoids on β-cell function [37]. Therefore, the use of TZDs, such as pioglitazone in GIDM has also been suggested [38]. These agents have been used for the long-term treatment of transplant-induced diabetes mellitus with some success in combination with other agents [38]. Vu et al. [39] also reported the added benefit of increased progression-free survival with the use of metformin and TZDs in acute lymphoblastic leukemia. However, the usefulness of metformin and pioglitazone in the treatment of transient corticosteroid-induced hyperglycemia is limited due to their slow onset of action [2].

INSULIN SECRETAGOGUES

Oral secretagogues such as sulfonylurea therapy do not specifically target postprandial hyperglycemia and thus long-acting agents may be associated with hypoglycemia if the patient does not eat meals regularly. In cases where hyperglycemia is induced by intermediate-acting glucocorticoids in 2 or more daily doses, by long-term preparations such as dexamethasone, or by intra-articular glucocorticoids, sulfonylureas may also be a useful therapeutic option because their hyperglycemic effect lasts for 24 hours and the risk of nocturnal hypoglycemia is relatively low [2]. Second-generation sulfonylureas, such as gliclazide, are mainstays of oral treatment due to their rapid onset of action [5]. Doses are most appropriately given at lunch time to target postprandial hyperglycemia. If hyperglycemia remains an issue at a near-maximum dose, initiation of insulin should be contemplated rather than the addition of an alternative oral hypoglycemic agent as they act too slowly to be beneficial in this circumstance. At this point, it would be appropriate to discuss treatment options with a team of diabetes specialists [5]. However, the prolonged duration of action of these agents may increase the risk of hypoglycemia when short-term and tapering doses of glucocorticoids are administered. Shorter-acting agents, such as meglinitide, nateglinide, or repaglinide, might be suitable in this regard [30]. Glinides allow minimal dose titration and have an immediate onset of action and a short effect duration, which allows adaptation to the hyperglycemic profile of the corticosteroids and reduces the risk of hypoglycemia in the morning, coinciding with the disappearance of the hyperglycemic action of corticosteroids [2]. For patients with mild hyperglycemia who are unable or unwilling to perform injections of insulin, a trial of short-acting secretagogues such as nateglinide or repaglinide taken before meals could be considered [5]. Their major disadvantage is the requirement for multiple daily doses.

INCRETIN MIMETICS

Incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors control glucose levels by stimulating insulin and inhibiting glucagon secretion in the fasting and postprandial setting. Drugs with incretin effects should probably be the drug of choice because of their immediate onset of action, their predominant effect on postprandial glycemia, and their low risk of hypoglycemia related to glucose-dependent effects [40]. A recent study found that concomitant treatment with a DPP-4 inhibitor improved various aspects of pancreatic islet-cell function in patients receiving high-dose prednisolone [41]. Furthermore, an intravenous infusion of exenatide prevented glucose intolerance induced by high doses of prednisolone in healthy patients and may be explored as a potential strategy to prevent GIDM [42].

INSULIN

Insulin therapy is often unavoidable when hyperglycemia is the result of the combined effects of insulin resistance induced by glucocorticoids and inhibition of the biosynthesis and release of insulin [16]. Transient corticosteroid use is one of the most common schedules of treatment, and is characterized by high initial doses and a gradual reduction as the underlying disease ameliorates. These types of glucocorticoid schedules can lead to initial moderate to severe hyperglycemia with rapid changes in glycemia in response to changes in the glucocorticoid dose. This hyperglycemia is temporary according to the duration of corticosteroid treatment. Therefore, the ideal hypoglycemic drug to address these situations should be potent, immediate-acting, and with an unlimited hypoglycemic action in order to control this rapid-onset hyperglycemia. In general, the effectiveness of the various oral hypoglycemic drugs in the treatment of new-onset glucocorticoid-induced hyperglycemia is limited [2]. This is due to their limited hypoglycemic power, which does not allow for the correction of hyperglycemia in many circumstances. Most available oral hypoglycemic drugs have a slow onset of action and/or a very limited or nonexistent ability to be titrated, leaving little capacity to adapt to major changes in the requirements of hypoglycemic action. Furthermore, the action profile of oral hypoglycemic drugs throughout the day does not usually coincide with the pattern of glucocorticoid-induced hyperglycemia. We should also note that many situations that require corticosteroids represent a formal contraindication to the use of oral hypoglycemic drugs. Patients with glycemia >200 mg/dL are frequently encountered and, in these cases, insulin is generally the drug of choice. In all other situations, insulin is usually the treatment of choice because of its efficacy and safety. It provides an immediate onset of action, an unlimited hypoglycemic power, and can be easily titrated. The different types of insulin available allow clinicians to prepare administration schedules with hypoglycemic effects appropriate for different corticosteroid schedules. The choice of the type and schedule of insulin should be determined by the previous hypoglycemic schedules of the patient and the type and schedule of corticosteroid established. The initial insulin dose and increments in insulin dosing should take into account the main variables that increase insulin resistance, which are the patient's weight and the dose of corticosteroid administered (Table 3) [30 43]. The algorithm for the management of corticosteroid-induced hyperglycemia that we propose takes into account all these aspects. Basal bolus insulin therapy remains the most flexible option for patients, and includes three components: basal insulin, prandial insulin, and a supplemental correction-factor insulin [44]. Both prandial and basal insulin regimens and premixed insulin are equally effective [11]. The conventional use of long-acting basal insulin with traditional weight-based dosing may cause nocturnal hypoglycemia [31]. More studies exploring the dose titration of insulin in patients on glucocorticoids possibly utilizing technology such as continuous glucose monitoring systems are needed. In general, however, a judicious step would be to time glucocorticoid administration to a midday or an evening meal with concomitant administration of intermediate-acting insulin. Subsequently, the insulin dose can be adjusted according to capillary glycemia with increases and/or decreases of around 20%. Changes in the dosage of glucocorticoids require parallel and proportional adjustments of the insulin dose [5 30]. In the outpatient setting, it is essential to instruct the patient and/or the patient's family regarding how to adjust the dose of insulin according to glycemia and changes in the dose of glucocorticoids. Once insulin therapy is initiated, it is recommended to adjust the basal insulin dose daily based on the glucose pattern and total amount of correction insulin in the past 24 hours [11].

MANAGEMENT OF HYPERGLYCEMIA IN PRE-EXISTING DIABETES

Glucocorticoids cause hyperglycemia in patients with or without pre-existing diabetes, but it remains to be determined how glucocorticoid-induced hyperglycemia in such patients should be managed and what the effects of management are. The control goals are those recommended for most patients with diabetes mellitus: preprandial glycemia <130 mg/dL, postprandial glycemia <180 mg/dL, and HbA1c <7% without hypoglycemia [26 27]. Patients who are diet-controlled may require an oral hypoglycemic agent, similarly to patients at a high risk of developing GIDM. Patients who are already on an oral hypoglycemic regimen may require dose intensification, addition of an alternative agent (with preference given to sulfonylureas and up-titrating the dose to the maximum), or initiation of insulin if despite these measures, blood glucose levels persistently remain >180 mg/dL. However, there is a risk of hypoglycemia when corticosteroid doses are reduced, and this risk is very high when a nocturnal dose of corticosteroids is removed. This therapeutic strategy can also be applied in T2DM patients who are well controlled with lifestyle measures or with oral hypoglycemic drugs that exacerbate their hyperglycemia during corticosteroid treatment. In these cases, the hypoglycemic drug selected would be added to the standard therapy, always considering drugs with synergistic effects with previous treatments and accounting for contraindications [2]. On starting insulin, the dose of sulfonylureas should be reduced to prevent hypoglycemia, while other oral hypoglycemic agents can be continued [5]. In patients previously treated with insulin, the usual schedule should be modified. The increment in the usual daily insulin dose will be estimated considering the patient's body weight, the preparation, and the glucocorticoid [30 43]. The calculated dose increment is added to the patient's usual total dose, distributing it in different administrations of insulin according to the usual insulin schedule and the glucocorticoid schedule [45]. Re-evaluation will need to take place daily as the effect of glucocorticoids on glycemic control is cumulative. In patients on a basal-bolus regimen (4 to 5 doses per day), it may be necessary to change the ratio from 50% basal and 50% bolus to 30% basal and 70% bolus, or to keep the same basal dose and increase the meal insulin [5]. In patients only on basal insulin with suboptimal glycemic control, the addition of rapid-acting insulin analogs with lunch and evening meals may be required [2]. For patients with persistent significant hyperglycemia with glucose levels >300 mg/dL, more aggressive insulin therapy is indicated, such as intravenous insulin infusion, a higher dose of insulin, or more frequent correction with rapid-acting insulin [46].

PATIENT EDUCATION

It should be ensured that all patients with diabetes and high-risk patients for GIDM have access to blood glucose monitoring, in order to prevent the development of hyperglycemic emergencies [5]. All patients should be educated on typical hyperglycemic symptoms that should prompt them to check their capillary blood glucose. Once the doses of glucocorticoids are being tapered down, the dosage of oral hypoglycemic agents or insulin should be appropriately reduced to prevent hypoglycemia. The appropriate follow-up of patients with previously unknown diabetes includes an HbA1c test 12 weeks following completion of glucocorticoid therapy to re-assess their diabetes status [17]. Patients on agents that can cause hypoglycemia need to check their blood glucose levels more frequently than usual 1 to 3 days after a glucocorticoid dose reduction, because it may take this amount of time for the glycemic effect of the glucocorticoid to diminish and for them to adjust their diabetes medication to the appropriate dose [47].

CONCLUSIONS

GIDM is a common and potentially harmful problem in clinical practice, affecting almost all medical specialties. However, its diagnosis and treatment are surprisingly undervalued by most healthcare professionals. The knowledge that hyperglycemia leads to longer hospital stays, delayed wound healing, increased infections, and higher mortality rates should encourage health-care providers to monitor its occurrence and to manage it appropriately. Similarly to T2DM in general, the principles of early detection and risk factor modification apply. Screening for GIDM should be considered in all patients (especially in those with risk factors) treated with medium to high doses of glucocorticoids. Diagnosing impaired fasting glucose or impaired glucose tolerance prior to the initiation of chronic glucocorticoids will better identify those who would benefit from glucocorticoid-sparing treatment, or if this is not an option, blood glucose monitoring while starting therapy. Together with, or after, lifestyle measures, hypoglycemic drugs with important insulin-sensitizing effects are indicated. Other oral hypoglycemic drugs or insulin therapy can be considered to be the drug of choice. Treatment, in most cases with insulin, should take into account the degree and pattern of hyperglycemia and the type, dose, and schedule of glucocorticoid used. Treatment should then be adjusted based on capillary glycemia and on changes in the dose of glucocorticoids. Moreover, it is essential to instruct the patient and/or the patient's family about how to perform these adjustments. Further investigation into the precise mechanism of glucocorticoid-induced insulin resistance will provide insights for future diabetes prevention efforts and targeted therapies.

Acknowledgements

ACKNOWLEDGMENT

This work was supported by the Dong-A University research fund.

Article information

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

References

1. Fathallah N, Slim R, Larif S, Hmouda H, BenSalem C. Drug-induced hyperglycaemia and diabetes. Drug Saf 2015;38:1153–1168. Article PubMed PDF
2. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Minambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes 2014;6:9–20. Article PubMed
3. Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 2014;30:96–102. Article PubMed PMC
4. Conn JW, Fajans SS. Influence of adrenal cortical steroids on carbohydrate metabolism in man. Metabolism 1956;5:114–127. PubMed
5. Mills E, Devendra S. Steroid-induced hyperglycaemia in primary care. London J Prim Care (Abingdon) 2015;7:103–106.Article PubMed PMC
6. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717–720. Article PubMed PMC
7. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006;12:358–362. Article PubMed PDF
8. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178–185. Article PubMed
9. Kim SY, Yoo CG, Lee CT, Chung HS, Kim YW, Han SK, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci 2011;26:264–267. Article PubMed PMC
10. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006;29:2728–2729. Article PubMed
11. Kwon S, Hermayer KL. Glucocorticoid-induced hyperglycemia. Am J Med Sci 2013;345:274–277. Article PubMed
12. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139–141. Article PubMed
13. Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab 2014;65:324–332. Article PubMed
14. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97–101. Article PubMed
15. Katsuyama T, Sada KE, Namba S, Watanabe H, Katsuyama E, Yamanari T, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract 2015;108:273–279. Article PubMed
16. Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am 2014;43:75–102. Article PubMed PMC
17. Brady VJ, Grimes D, Armstrong T, LoBiondo-Wood G. Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review. Oncol Nurs Forum 2014;41:E355–E365. Article PubMed PDF
18. Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983;72:1814–1820. Article PubMed PMC
19. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009;39:81–93. Article PubMed
20. Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000;49:1700–1708. Article PubMed
21. Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998;47:3–6.Article
22. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007;275:43–61. Article PubMed
23. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002;32(Suppl 3):14–23. Article PubMed
24. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997;100:2094–2098. Article PubMed PMC
25. van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schaap J, Nassander UK, et al. Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol 2010;162:729–735. Article PubMed
26. American Diabetes Association. 14. Diabetes care in the hospital. Diabetes Care 2017;40(Suppl 1):S120–S127. Article PubMed
27. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16–38. Article PubMed
28. Baldwin D, Apel J. Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. Curr Diab Rep 2013;13:114–120. Article PubMed PDF
29. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 2017;40(Suppl 1):S11–S24. Article PubMed
30. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469–474. Article PubMed PDF
31. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011;96:1789–1796. Article PubMed
32. Valderhaug TG, Jenssen T, Hartmann A, Midtvedt K, Holdaas H, Reisaeter AV, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009;88:429–434. Article PubMed
33. Imatoh T, Sai K, Hori K, Segawa K, Kawakami J, Kimura M, et al. Development of a novel algorithm for detecting glucocorticoid-induced diabetes mellitus using a medical information database. J Clin Pharm Ther 2017;42:215–220. Article PubMed
34. Gonzalez-Gonzalez JG, Mireles-Zavala LG, Rodriguez-Gutierrez R, Gomez-Almaguer D, Lavalle-Gonzalez FJ, Tamez-Perez HE, et al. Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients. Diabetol Metab Syndr 2013;5:18Article PubMed PMC PDF
35. Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? Diabetes Metab J 2015;39:273–282. Article PubMed PMC
36. Seelig E, Meyer S, Timper K, Nigro N, Bally M, Pernicova I, et al. Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol 2017;176:349–358. Article PubMed
37. Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract 2002;58:87–96. Article PubMed
38. Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004;4:2135–2138. Article PubMed
39. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, et al. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2012;12:355–362. Article PubMed PMC
40. Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J Diabetes 2010;1:99–100. Article PubMed PMC
41. van Genugten RE, van Raalte DH, Muskiet MH, Heymans MW, Pouwels PJ, Ouwens DM, et al. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. Eur J Endocrinol 2014;170:429–439. Article PubMed
42. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011;34:412–417. Article PubMed PMC
43. Saigi I, Perez A. Management of glucocorticoid induced hyperglycemia. Rev Clin Esp 2010;210:397–403. Article PubMed
44. Burt MG, Drake SM, Aguilar-Loza NR, Esterman A, Stranks SN, Roberts GW. Efficacy of a basal bolus insulin protocol to treat prednisolone-induced hyperglycaemia in hospitalised patients. Intern Med J 2015;45:261–266. Article PubMed
45. Grommesh B, Lausch MJ, Vannelli AJ, Mullen DM, Bergenstal RM, Richter SA, et al. Hospital insulin protocol aims for glucose control in glucocorticoid-induced hyperglycemia. Endocr Pract 2016;22:180–189. Article PubMed
46. Hawkins K, Donihi AC, Korytkowski MT. Glycemic management in medical and surgical patients in the non-ICU setting. Curr Diab Rep 2013;13:96–106. Article PubMed PDF
47. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med 2011;78:748–756. Article PubMed

Table 1

Risk Factors for Glucocorticoid-Induced Diabetes Mellitus

Higher dose of glucocorticoid treatment (prednisolone >20 mg, hydrocortisone >50 mg, dexamethasone >4 mg)

Longer duration of glucocorticoid treatment

Advanced age

High body mass index

Previous glucose intolerance or impaired glucose tolerance

Personal history of gestational diabetes or previous glucocorticoid-induced hyperglycemia

Family history of diabetes mellitus

Hemoglobin A1c ≥6%

Table 2

Mechanisms of Glucocorticoid-Induced Diabetes Mellitus

Reduced peripheral insulin sensitivity and/or promotion of weight gain

Increase in glucose production through promotion of hepatic gluconeogenesis

Destruction of pancreatic cells, leading to β-cell injury (inflammation)

β-Cell dysfunction

Impaired insulin release

Inhibited glyceroneogenesis

Increase in fatty acids

Table 3

Estimation of the Initial Dose of Insulin in Glucocorticoid- Induced Hyperglycemia, According to the Type and Dose of Glucocorticoids

Prednisone dose, mg/day	Dexamethasone dose, mg/day	Insulin NPH, glargine/detemir dose, IU/kg/day
≥40	≥8	0.4
30	6	0.3
20	4	0.2
10	2	0.1

NPH, neutral protamine Hagedorn.

Figure & Data

References

Citations

Citations to this article as recorded by

Continuous Glucose Monitoring of Steroid-Induced Hyperglycemia in Patients With Dermatologic Diseases
Monika Kleinhans, Lea Jessica Albrecht, Sven Benson, Dagmar Fuhrer, Joachim Dissemond, Susanne Tan
Journal of Diabetes Science and Technology.2024; 18(4): 904. CrossRef
COVID‐19 associated mucormycosis surge: A review on multi‐pathway mechanisms
Mohsen Pourazizi, Atousa Hakamifard, Alireza Peyman, Rasoul Mohammadi, Shakiba Dehghani, Najmeh Tavousi, Nastaran‐Sadat Hosseini, Hamed Azhdari Tehrani, Bahareh Abtahi‐Naeini
Parasite Immunology.2024;[Epub] CrossRef
Drug-induced hyperglycemia and diabetes
Marie-Anne Heurtebize, Jean-Luc Faillie
Therapies.2024; 79(2): 221. CrossRef
Immunosuppression in solid organ–transplant recipients and impact on nutrition support
Nicole K. Wilson, Ann D. Kataria
Nutrition in Clinical Practice.2024; 39(1): 109. CrossRef
The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes
Vaishali Limbachia, Ian Nunney, Daniel J. Page, Hannah A. Barton, Leena K. Patel, Georgia N. Thomason, Stephan L. Green, Kieran F.J. Lewis, Ketan Dhatariya
Clinical Therapeutics.2024; 46(2): e59. CrossRef
Incidence and Characteristics of the Hyperosmolar Hyperglycemic State: A Danish Cohort Study
Emilie V. Rosager, Amalia Lærke K. Heltø, Cathrine U. Fox Maule, Lennart Friis-Hansen, Janne Petersen, Finn E. Nielsen, Steen B. Haugaard, Rasmus Gregersen
Diabetes Care.2024; 47(2): 272. CrossRef
Cortisol levels across the lifespan in common marmosets (Callithrix jacchus)
Matthew Lopez, Amaya Seidl, Kimberley A. Phillips
American Journal of Primatology.2024;[Epub] CrossRef
Belimumab in a Patient with Systemic Lupus Erythematosus with Juvenile Onset and Steroid-induced Diabetes: Clinical Case
Maria I. Kaleda, Irina P. Nikishina, Alesya V. Firsa
Current Pediatrics.2024; 22(6): 546. CrossRef
Optimal initial insulin dosage for managing steroid-induced hyperglycemia in hospitalized COVID-19 patients: A retrospective single-center study
Nuttavadee Ketaroonrut, Sasisopin Kiertiburanakul, Chutintorn Sriphrapradang
SAGE Open Medicine.2024;[Epub] CrossRef
Extended-Release Versus Immediate-Release Triamcinolone Acetonide in Patients Who Have Knee Osteoarthritis and Type 2 Diabetes Mellitus
Andrew I. Spitzer, Helena W. Rodbard, Sheikh Usman Iqbal, Masato Nakazawa, Mary DiGiorgi, Roy Winston
The Journal of Arthroplasty.2024; 39(9): S218. CrossRef
Important aspects of carbohydrate metabolism disorders development in hematology/oncology patients during therapy with glucocorticosteroids: a review of the literature
N. T. Vatutin, E. V. Sklyannaya, V. V. Gribov
Oncohematology.2024; 19(2): 118. CrossRef
The safety and use of perioperative dexamethasone in the perioperative management of primary sporadic supratentorial meningiomas
Felix Arlt, Alim Emre Basaran, Markus Vogel, Martin Vychopen, Clemens Seidel, Alonso Barrantes-Freer, Erdem Güresir, Johannes Wach
Frontiers in Oncology.2024;[Epub] CrossRef
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial
Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N. Brown, Szilard Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
British Journal of Clinical Pharmacology.2024; 90(8): 1921. CrossRef
Continuous glucose monitoring profile in COVID-19 patients with and without diabetes receiving methylprednisolone
Xingxing He, Guangchen Duan, Jingyi Lu, Yaxin Wang, Jinghao Cai, Yiqing Tong, Wei Wu, Xiaojing Ma, Qiming Feng, Jian Zhou
Endocrine.2024;[Epub] CrossRef
DISFUNÇÕES RESPIRATÓRIAS FELINAS
Felipe Gaia de Sousa, Juliana Uchôa Ribeiro, Suzane Lilian Beier, Myrian Kátia Iser Teixeira
Veterinária e Zootecnia.2024; 31: 1. CrossRef
Letter to the Editor From Hao and Xue: “Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy”
Lu Hao, Jisu Xue
The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
Review Artikel: Pengaruh Glukokortioid Terhadap Glukosa Darah Pasien Diabetes Melitus Tipe 2
Novia Ariani Dewi, Arina Titami
Jurnal Farmasi SYIFA.2024; 2(2): 68. CrossRef
Diabetic ketoacidosis in a patient with type 2 diabetes induced by multiple triggers: a case report and implications for clinical practice
Konstantinos Kitsios, Christina‐Maria Trakatelli
Practical Diabetes.2024; 41(3): 27. CrossRef
Endocrine Disorders and Peripheral Arterial Disease – A Series of Reviews Cushing Syndrome-Cortisol Excess
Poredoš P, Schernthaner GH, Blinc A, Mikhailidis DP, Jensterle M, Anagnostis P, Antignani PL, Bajuk Studen K, Šabović M, Ježovnik MK
Current Vascular Pharmacology.2024; 22(4): 236. CrossRef
Sars-Cov2 Induced Biochemical Mechanisms in Liver Damage and Intestinal Lesions
Liudmila V. Spirina, Vladimir N. Masunov, Denis A. Dyakov, Olga E. Akbasheva, Amina Y. Kebekbayeva, Igor Yu. Shuvalov, Nadezhda V. Masunova, Irina V. Kovaleva, Yumzhana Dagbaeva
Indian Journal of Clinical Biochemistry.2023; 38(4): 437. CrossRef
Mouse Pancreatic Peptide Hormones Probed at the Sub-Single-Islet Level: The Effects of Acute Corticosterone Treatment
Aleksandra Antevska, Connor C. Long, Samuel D. Dupuy, J. Jason Collier, Michael D. Karlstad, Thanh D. Do
Journal of Proteome Research.2023; 22(1): 235. CrossRef
Type 1 and other types of diabetes mellitus in the perioperative period. What the anaesthetist should know
Robert van Wilpe, Abraham H. Hulst, Sarah.E. Siegelaar, J. Hans DeVries, Benedikt Preckel, Jeroen Hermanides
Journal of Clinical Anesthesia.2023; 84: 111012. CrossRef
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis
Naomi J. Patel, Veronica Tozzo, John M. Higgins, John H. Stone
Arthritis & Rheumatology.2023; 75(4): 586. CrossRef
Characterization, evolution and risk factors of diabetes and prediabetes in a pediatric cohort of renal and liver transplant recipients
Sophie Welsch, Virginie Mailleux, Priscilla le Hardy de Beaulieu, Nadejda Ranguelov, Nathalie Godefroid, Annie Robert, Xavier Stephenne, Isabelle Scheers, Raymond Reding, Etienne M. Sokal, Philippe A. Lysy
Frontiers in Pediatrics.2023;[Epub] CrossRef
The safety of perioperative dexamethasone with antiemetic dosage in surgical patients with diabetes mellitus: a systematic review and meta-analysis
Qian-Yun Pang, Jing-Yun Wang, Xiao-Long Liang, Yan Jiang, Hong-Liang Liu
Perioperative Medicine.2023;[Epub] CrossRef
Link between Blood Cell-Associated Inflammatory Indices and Chemotherapy-Induced Hyperglycemia in Women Affected with Breast Cancer: Clinical Studies
Krishna Prasad, Suresh Rao, Sanath Kumar Hegde, Thomas George, Rhea Katherine D'souza, Sucharitha Suresh, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2023; 12(02): 118. CrossRef
Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer
Dana Mahin, Sayeh Moazami Lavasani, Leon Cristobal, Niki Tank Patel, Mina Sedrak, Daphne Stewart, James Waisman, Yuan Yuan, Wai Yu, Raynald Samoa, Nora Ruel, Susan E. Yost, Hayley Lee, Sung Hee Kil, Joanne E. Mortimer
Journal of Clinical Medicine.2023; 12(5): 1906. CrossRef
Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats
Priscila L. Zimath, Milena S. Almeida, Maciel A. Bruxel, Alex Rafacho
Biochemical Pharmacology.2023; 210: 115486. CrossRef
Regeneration of an infected skin wound under conditions of experimental steroid hyperglycemia
L. A. Balykova, V. I. Inchina, T. V. Tarasova, D. A. Khaydar, L. M. Mosina, I. V. Saushev, A. V. Kuchuk, A. Mutvakel, I. V. Begoulov, R. S. Tarasov, P. V. Ageev, D. S. Ovchenkov
Research and Practical Medicine Journal.2023; 10(1): 90. CrossRef
Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav
International Journal of Diabetes in Developing Countries.2023; 43(6): 856. CrossRef
Risk for Newly Diagnosed Type 2 Diabetes Mellitus after COVID-19 among Korean Adults: A Nationwide Matched Cohort Study
Jong Han Choi, Kyoung Min Kim, Keeho Song, Gi Hyeon Seo
Endocrinology and Metabolism.2023; 38(2): 245. CrossRef
Zein nanoparticles as oral carrier for mometasone furoate delivery
Priscila Zimath, Soraia Pinto, Sofia Dias, Alex Rafacho, Bruno Sarmento
Drug Delivery and Translational Research.2023; 13(11): 2948. CrossRef
Impact of Diabetes in COVID-19 Associated Mucormycosis and its Management: A Non-Systematic Literature Review
Muhammed Rashid, Asha K. Rajan, Girish Thunga, Vishal Shanbhag, Sreedharan Nair
Current Diabetes Reviews.2023;[Epub] CrossRef
Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation
Abdulla Ahmed, Kriss Kania, Hebba Abdul Rahim, Salaheldin Ahmed, Göran Rådegran
ESC Heart Failure.2023; 10(4): 2427. CrossRef
Part II: Interactive case: Drug‐induced endocrine disorders
Amy C. Donihi
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.2023; 6(6): 663. CrossRef
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Riccardo Pofi, Giorgio Caratti, David W Ray, Jeremy W Tomlinson
Endocrine Reviews.2023; 44(6): 975. CrossRef
Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
Yu-Jih Su, Hui-Ming Chen, Tien-Ming Chan, Tien-Tsai Cheng, Shan-Fu Yu, Jia-Feng Chen, Chun-Yu Lin, Chung-Yuan Hsu
RMD Open.2023; 9(3): e003045. CrossRef
The Prevalence of Diabetes Mellitus Type II (DMII) in the Multiple Sclerosis Population: A Systematic Review and Meta-Analysis
Vasileios Giannopapas, Lina Palaiodimou, Dimitrios Kitsos, Georgia Papagiannopoulou, Konstantina Stavrogianni, Athanasios Chasiotis, Maria Kosmidou, John S. Tzartos, George P. Paraskevas, Daphne Bakalidou, Georgios Tsivgoulis, Sotirios Giannopoulos
Journal of Clinical Medicine.2023; 12(15): 4948. CrossRef
Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities
Mihaela Simona Popoviciu, Lorena Paduraru, Raluca Marinela Nutas, Alexandra Maria Ujoc, Galal Yahya, Kamel Metwally, Simona Cavalu
International Journal of Molecular Sciences.2023; 24(16): 12676. CrossRef
Usefulness of Indian Diabetes Risk Score in Predicting Treatment-Induced Hyperglycemia in Women Undergoing Adjuvant Chemotherapy for Breast Cancer
Krishna Prasad, Sanath Hegde, Suresh Rao, Rhea Katherine D'souza, Thomas George, Manjeshwar Shrinath Baliga, Sucharitha Suresh
South Asian Journal of Cancer.2023;[Epub] CrossRef
The inverse association between DNA gaps and HbA1c levels in type 2 diabetes mellitus
Jirapan Thongsroy, Apiwat Mutirangura
Scientific Reports.2023;[Epub] CrossRef
Corticosteroids for COVID-19: worth it or not?
Fariya Akter, Yusha Araf, Mohammad Jakir Hosen
Molecular Biology Reports.2022; 49(1): 567. CrossRef
Evidence-Based Management of Steroid-Induced Hyperglycemia in the Inpatient Setting
Lauren Longaker, Jennifer N. Clements
ADCES in Practice.2022; 10(1): 40. CrossRef
Is Methylprednisolone Acetate-Related Insulin Resistance Preventable in Cats?
Karine Marchioro Leal, Mariana Barcelos Rocha, Fernanda Venzon Varela, Luana Rodrigues, Priscila Viau Furtado, Fernanda Vieira Amorim da Costa, Álan Gomes Pöppl
Topics in Companion Animal Medicine.2022; 49: 100648. CrossRef
Ac3IV, a V1a and V1b receptor selective vasopressin analogue, protects against hydrocortisone-induced changes in pancreatic islet cell lineage
Shruti Mohan, Ryan A. Lafferty, Peter R. Flatt, R. Charlotte Moffett, Nigel Irwin
Peptides.2022; 152: 170772. CrossRef
Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations
Thiago Bosco Mendes, Alexandre Barbosa Câmara-de-Souza, Bruno Halpern
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef
When therapeutic drugs lead to diabetes
Bruno Fève, André J. Scheen
Diabetologia.2022; 65(5): 751. CrossRef
Nutrition implications of intrinsic restrictive lung disease
Sylvia Rinaldi, Christine Balsillie, Cassandra Truchon, Awatif AL‐Mubarak, Marco Mura, Janet Madill
Nutrition in Clinical Practice.2022; 37(2): 239. CrossRef
Coinfection by Aspergillus and Mucoraceae Species in Two Cases of Acute Rhinosinusitis as a Complication of COVID-19
Payam Tabarsi, Somayeh Sharifynia, Mihan Pourabdollah Toutkaboni, Zahra Abtahian, Mohammad Rahdar, Arefeh Sadat Mirahmadian, Atousa Hakamifard, Simone Cesaro
Case Reports in Medicine.2022; 2022: 1. CrossRef
Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer
Vasileios Angelis, Stephen R. D. Johnston, Amin Ardestani, Kathrin Maedler
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Impact of Deranged Glucose Metabolism and Diabetes in the Pathogenesis and Prognosis of the Novel SARS-CoV-2: A Systematic Review of Literature
Victor O. Ukwenya, Sunday A. Adelakun, Temiloluwa A. Fuwape, Ayotunde S. Adeagbo
Current Diabetes Reviews.2022;[Epub] CrossRef
Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
Rahul Gupta
Bulletin of the National Research Centre.2022;[Epub] CrossRef
Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon
Fei Peng, Xin Li, Fang Xiao, Ruxing Zhao, Zheng Sun
Trends in Neurosciences.2022; 45(6): 471. CrossRef
3,3′,4,5′-Tetramethoxy-trans-stilbene Improves Insulin Resistance by Activating the IRS/PI3K/Akt Pathway and Inhibiting Oxidative Stress
Yi Tan, Lingchao Miao, Jianbo Xiao, Wai San Cheang
Current Issues in Molecular Biology.2022; 44(5): 2175. CrossRef
Management of Glucocorticoid-Induced Hyperglycemia
Parag Shah, Sanjay Kalra, Yogesh Yadav, Nilakshi Deka, Tejal Lathia, Jubbin Jagan Jacob, Sunil Kumar Kota, Saptarshi Bhattacharya, Sharvil S Gadve, KAV Subramanium, Joe George, Vageesh Iyer, Sujit Chandratreya, Pankaj Kumar Aggrawal, Shailendra Kumar Sing
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1577. CrossRef
Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study
Marcos Tadashi Kakitani Toyoshima, Priscilla Cukier, Alexandre Barbosa Câmara de Souza, Juliana Pereira, Ana Oliveira Hoff, Marcia Nery
einstein (São Paulo).2022;[Epub] CrossRef
Mucormycosis in the COVID-19 Environment: A Multifaceted Complication
Rohit Sharma, Praveen Kumar, Abdur Rauf, Ashun Chaudhary, Pradeep Kumar Prajapati, Talha Bin Emran, Clara Mariana Gonçalves Lima, Carlos Adam Conte-Junior
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
Black pepper oil (Piper nigrum L.) mitigates dexamethasone induced pancreatic damage via modulation of oxidative and nitrosative stress
Mona F. Mahmoud, Asmaa M. Elmaghraby, Noura Ali, Islam Mostafa, Assem M. El-Shazly, Mohamed A.O. Abdelfattah, Mansour Sobeh
Biomedicine & Pharmacotherapy.2022; 153: 113456. CrossRef
Various Coated Barrier Membranes for Better Guided Bone Regeneration: A Review
Ji-Youn Kim, Jun-Beom Park
Coatings.2022; 12(8): 1059. CrossRef
RETROSPECTIVE STUDY ON GLYCAEMIC CONTROL OF THE MIDDLE-AGED PATIENTS RECEIVING STEROID THERAPY IN COVID ICU
Sayantan Dutta, Sumanta Ghosh Maulik, Jisnu Nayak
PARIPEX INDIAN JOURNAL OF RESEARCH.2022; : 1. CrossRef
Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy
Joachim Baech, Marianne Tang Severinsen, Andreas K. Øvlisen, Henrik Frederiksen, Peter Vestergaard, Christian Torp-Pedersen, Judit Jørgensen, Michael Roost Clausen, Christian B. Poulsen, Peter Brown, Anne Ortved Gang, Robert Schou Pedersen, Karin Ekström
Blood Advances.2022; 6(15): 4427. CrossRef
Diabètes pharmaco-induits : quatre classes médicamenteuses au cœur de notre pratique clinique
André J. Scheen, Bruno Fève
Médecine des Maladies Métaboliques.2022; 16(7): 627. CrossRef
Dexamethasone-Induced Derangement in Some Liver Function Parameters
Timothy Danboyi, Abdulazeez Jimoh, Evelyn Hassan-Danboyi, Abdul Wahab Alhassan, Augustine Banlibo Dubo
Nigerian Journal of Experimental and Clinical Biosciences.2022; 10(3): 74. CrossRef
Polypharmacy Patterns in Multimorbid Older People with Cardiovascular Disease: Longitudinal Study
Noemí Villén, Albert Roso-Llorach, Carlos Gallego-Moll, Marc Danes-Castells, Sergio Fernández-Bertolin, Amelia Troncoso-Mariño, Monica Monteagudo, Ester Amado, Concepción Violán
Geriatrics.2022; 7(6): 141. CrossRef
Increased risk of type 2 diabetes in patients with systemic lupus erythematosus: A nationwide cohort study in Taiwan
Yeong-Jang Lin, Chih-Chiang Chien, Chung-Han Ho, Hung-An Chen, Chao-Yu Chen
Medicine.2022; 101(51): e32520. CrossRef
Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety
Angélica María Téllez Arévalo, Abraham Quaye, Luis Carlos Rojas-Rodríguez, Brian D. Poole, Daniela Baracaldo-Santamaría, Claudia M. Tellez Freitas
Medicina.2022; 59(1): 56. CrossRef
Effect of Ficus lacor Buch. Ham. Fruit Extract on Dexamethasone Induced Insulin Resistant Rats
V. S. Mule, N. S. Naikwade
Research Journal of Pharmacy and Technology.2022; : 5559. CrossRef
Prednisolone-induced diabetes mellitus in the cat: a historical cohort
Sivert Nerhagen, Hanne L Moberg, Gudrun S Boge, Barbara Glanemann
Journal of Feline Medicine and Surgery.2021; 23(2): 175. CrossRef
Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy
Mattia Quattrocelli, Aaron S. Zelikovich, Isabella M. Salamone, Julie A. Fischer, Elizabeth M. McNally
Journal of Neuromuscular Diseases.2021; 8(1): 39. CrossRef
A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes
Thomas Forst, Pratik Choudhary, Doron Schneider, Bruno Linetzky, Paolo Pozzilli
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Incidence and control of steroid-induced hyperglycaemia in hospitalised patients at a tertiary care centre for lung diseases
Matej Dobravc Verbič, Jasna Gruban, Mojca Kerec Kos
Pharmacological Reports.2021; 73(3): 796. CrossRef
Epigenetics in blood–brain barrier disruption
Stephanie A. Ihezie, Iny Elizebeth Mathew, Devin W. McBride, Ari Dienel, Spiros L. Blackburn, Peeyush Kumar Thankamani Pandit
Fluids and Barriers of the CNS.2021;[Epub] CrossRef
Risk factors for corticosteroid-induced hyperglycemia requiring insulin therapy in hospitalized patients without diabetes
Catherine Li, Patricia Krause, Gretchen Stern
Endocrine.2021; 73(2): 476. CrossRef
Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women
Wojciech Krzyzanski, Mark A. Milad, Alan H. Jobe, Thomas Peppard, Robert R. Bies, William J. Jusko
Journal of Pharmacokinetics and Pharmacodynamics.2021; 48(3): 411. CrossRef
Hormonal activity in commonly used Black hair care products: evaluating hormone disruption as a plausible contribution to health disparities
Tamarra James-Todd, Lisa Connolly, Emma V. Preston, Marlee R. Quinn, Monika Plotan, Yuling Xie, Bharathi Gandi, Shruthi Mahalingaiah
Journal of Exposure Science & Environmental Epidemiology.2021; 31(3): 476. CrossRef
New‐onset diabetes in “long COVID”
Thirunavukkarasu Sathish, Mary Chandrika Anton, Tharsan Sivakumar
Journal of Diabetes.2021; 13(8): 693. CrossRef
Glucocorticoid-Induced Exacerbation of Mycobacterial Infection Is Associated With a Reduced Phagocytic Capacity of Macrophages
Yufei Xie, Jiajun Xie, Annemarie H. Meijer, Marcel J. M. Schaaf
Frontiers in Immunology.2021;[Epub] CrossRef
Glucocorticoid signaling in pancreatic islets modulates gene regulatory programs and genetic risk of type 2 diabetes
Anthony Aylward, Mei-Lin Okino, Paola Benaglio, Joshua Chiou, Elisha Beebe, Jose Andres Padilla, Sharlene Diep, Kyle J. Gaulton, Michael L. Stitzel
PLOS Genetics.2021; 17(5): e1009531. CrossRef
A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital
Felix Aberer, Daniel A. Hochfellner, Harald Sourij, Julia K. Mader
Journal of Clinical Medicine.2021; 10(10): 2154. CrossRef
Combination of Bawang Dayak Extract and Acarbose against Male White Rat Glucose Levels
Aditya Maulana Perdana Putra, Ratih Pratiwi Sari, Siska Musiam
Borneo Journal of Pharmacy.2021; 4(2): 84. CrossRef
Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India
Subhash Wangnoo, M. Shunmugavelu, Sagili Vijaya Bhaskar Reddy, Vijay Negalur, Shreerang Godbole, Vinay K Dhandhania, Nareen Krishna, Kumar Gaurav
Endocrine and Metabolic Science.2021; 4: 100102. CrossRef
Genome-Wide Differential Methylation Profiles from Two Terpene-Rich Medicinal Plant Extracts Administered in Osteoarthritis Rats
Younhee Shin, Sathiyamoorthy Subramaniyam, Jin-Mi Chun, Ji-Hyeon Jeon, Ji-Man Hong, Hojin Jung, Boseok Seong, Chul Kim
Plants.2021; 10(6): 1132. CrossRef
Chronic glucocorticoid treatment induces hepatic lipid accumulation and hyperinsulinaemia in part through actions on AgRP neurons
Erika Harno, Charlotte Sefton, Jonathan R. Wray, Tiffany-Jayne Allen, Alison Davies, Anthony P. Coll, Anne White
Scientific Reports.2021;[Epub] CrossRef
Endocrine Disorders in Autoimmune Rheumatological Diseases: A Focus on Thyroid Autoimmune Diseases and on the Effects of Chronic Glucocorticoid Treatment
Filippo Egalini, Mirko Parasiliti Caprino, Giulia Gaggero, Vincenzo Cappiello, Jacopo Giannelli, Ruth Rossetto Giaccherino, Loredana Pagano, Roberta Giordano
Endocrines.2021; 2(3): 171. CrossRef
Current cancer therapies and their influence on glucose control
Carly Yim, Kerry Mansell, Nassrein Hussein, Terra Arnason
World Journal of Diabetes.2021; 12(7): 1010. CrossRef
Immune‐checkpoint inhibitor‐associated diabetes compared to other diabetes types ‐ A prospective, matched control study
Sascha R. Tittel, Katharina Laubner, Sebastian M. Schmid, Stefan Kress, Sigrun Merger, Wolfram Karges, Frank J. Wosch, Marcus Altmeier, Marianne Pavel, Reinhard W. Holl
Journal of Diabetes.2021; 13(12): 1007. CrossRef
Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis
Hariprasath Prakash, Anna Skiada, Raees Ahmad Paul, Arunaloke Chakrabarti, Shivaprakash Mandya Rudramurthy
Journal of Fungi.2021; 7(8): 616. CrossRef
Antioxidant Effects of L-citrulline Supplementation in High-fat Diet- and Dexamethasone-induced Type-2 Diabetes Mellitus in Wistar Rats (Rattus norvegicus)
Evelyn Hassan-Danboyi, Abdulazeez Jimoh, Abdulwahab Alhassan, Timothy Danboyi, Kabir Ahmed Mohammed, Augustine Banlibo Dubo, Jamilu Haruna, Bulus Billy Yakubu
Nigerian Journal of Experimental and Clinical Biosciences.2021; 9(2): 95. CrossRef
ASSESSMENT OF THE POSSIBLE CAUSES OF DIABETES MELLITUS DEVELOPED IN PATIENTS POST COVID-19 TREATMENT IN A TERTIARY CARE HOSPITAL
KHUJITH RAJUENI, RUTUJA AMBEKAR, HITENDRAPAL SOLANKI, ABDULRAHAMAN ABUBAKAR MOMIN, SUNITA PAWAR
International Journal of Pharmacy and Pharmaceutical Sciences.2021; : 11. CrossRef
Potent Anti-Inflammatory, Arylpyrazole-Based Glucocorticoid Receptor Agonists That Do Not Impair Insulin Secretion
Brandon J. Kennedy, Ashley M. Lato, Alexander R. Fisch, Susan J. Burke, Justin K. Kirkland, Carson W. Prevatte, Lee E. Dunlap, Russell T. Smith, Konstantinos D. Vogiatzis, J. Jason Collier, Shawn R. Campagna
ACS Medicinal Chemistry Letters.2021; 12(10): 1568. CrossRef
Diabetes in COVID-19 patients: challenges and possible management strategies
Riyan Al Islam Reshad, Sumaiya Hafiz Riana, Mohammad Al-baruni Chowdhury, Abu Tayab Moin, Faruque Miah, Bishajit Sarkar, Nurnabi Azad Jewel
The Egyptian Journal of Bronchology.2021;[Epub] CrossRef
Excess Body Mass—A Factor Leading to the Deterioration of COVID-19 and Its Complications—A Narrative Review
Weronika Gryczyńska, Nikita Litvinov, Bezawit Bitew, Zuzanna Bartosz, Weronika Kośmider, Paweł Bogdański, Damian Skrypnik
Viruses.2021; 13(12): 2427. CrossRef
Risk of Future Type 2 Diabetes Mellitus in Patients Developing Steroid-Induced Hyperglycemia During Hospitalization for Chronic Obstructive Pulmonary Disease Exacerbation
Jagriti Upadhyay, Nitin Trivedi, Amos Lal
Lung.2020; 198(3): 525. CrossRef
Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion
Kecheng Zhu, Yumei Zhang, Juan Zhang, Feiye Zhou, Linlin Zhang, Shushu Wang, Qin Zhu, Qianqian Liu, Xiao Wang, Libin Zhou
Toxicology Letters.2020; 320: 19. CrossRef
Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease
Mohamad Isam Saeed, Josefin Eklöf, Imane Achir, Pradeesh Sivapalan, Howraman Meteran, Anders Løkke, Tor Biering‐Sørensen, Filip Krag Knop, Jens‐Ulrik Stæhr Jensen
Diabetes, Obesity and Metabolism.2020; 22(8): 1348. CrossRef
Patterns of Glucose Fluctuation are Challenging in Patients Treated for Non-Hodgkin’s Lymphoma

Andreja Marić, Tanja Miličević, Jelena Vučak Lončar, Davor Galušić, Maja Radman
International Journal of General Medicine.2020; Volume 13: 131. CrossRef
Metformin's effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers
Lucy A Ochola, David G Nyamu, Eric M Guantai, Irene W Weru
Journal of Oncology Pharmacy Practice.2020; 26(4): 823. CrossRef
Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with
Carina Kirstine Klarskov, Helga Holm Schultz, Frederik Persson, Tomas Møller Christensen, Thomas Peter Almdal, Ole Snorgaard, Katrine Bagge Hansen, Ulrik Pedersen-Bjergaard, Peter Lommer Kristensen
BMC Endocrine Disorders.2020;[Epub] CrossRef
Implementation of a Weight-Based Protocol for the Management of Steroid-Induced Hyperglycemia
Alyson K. Myers, Mahmuda Khan, Sebastian Choi, Patricia Garnica, Guillaume Stoffels, Amanda Lin
American Journal of Therapeutics.2020; 27(4): e392. CrossRef
The difference between steroid diabetes mellitus and type 2 diabetes mellitus: a whole-body 18F-FDG PET/CT study
Qingqing Zhao, Jinxin Zhou, Yu Pan, Huijun Ju, Liying Zhu, Yang Liu, Yifan Zhang
Acta Diabetologica.2020; 57(11): 1383. CrossRef
Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis
Jianhua Wu, Sarah L Mackie, Mar Pujades-Rodriguez
BMJ Open Diabetes Research & Care.2020; 8(1): e001220. CrossRef
Diabète et corticoïdes : nouveautés et aspects pratiques
M. Bastin, F. Andreelli
La Revue de Médecine Interne.2020; 41(9): 607. CrossRef
Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes
Janine Alessi, Giovana B. de Oliveira, Beatriz D. Schaan, Gabriela H. Telo
Diabetology & Metabolic Syndrome.2020;[Epub] CrossRef
Glycemic Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Subjects With Parental Diabetes
Ebenezer Nyenwe, Deirdre James, Jim Wan, Sam Dagogo-Jack
Journal of the Endocrine Society.2020;[Epub] CrossRef
Outcomes of Hospitalized Patients with Glucocorticoid-Induced Hyperglycemia—A Retrospective Analysis
Neele Delfs, Tristan Struja, Sandra Gafner, Thaddaeus Muri, Ciril Baechli, Philipp Schuetz, Beat Mueller, Claudine Angela Blum
Journal of Clinical Medicine.2020; 9(12): 4079. CrossRef
Incidence of Hyperglycemia/Secondary Diabetes in Women who have Undergone Curative Chemotherapy for Breast Cancer: First Study from India
Suresh Rao, Krishna Prasad, Soniya Abraham, Thomas George, Supreeth Kakkaje Chandran, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2020; 09(03): 130. CrossRef
Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study
Imadeldin Elfaki, Rashid Mir, Faisel Mohammed Abu-Duhier, Chandan Kumar Jha, Adel Ibrahim Ahmad Al-Alawy, Abdullatif Taha Babakr, Salem Abd El-Hadi Habib
Current Drug Metabolism.2020; 21(14): 1152. CrossRef
What is the optimal time for measuring glucose concentration to detect steroid-induced hyperglycemia in patients with rheumatic diseases?
Güven Barış Cansu, Döndü Üsküdar Cansu, Bengür Taşkıran, Şule Yaşar Bilge, Muzaffer Bilgin, Cengiz Korkmaz
Clinical Biochemistry.2019; 67: 33. CrossRef
Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats
Yohei Asada, Takeshi Takayanagi, Tsukasa Kawakami, Eisuke Tomatsu, Atsushi Masuda, Yasumasa Yoshino, Sahoko Sekiguchi-Ueda, Megumi Shibata, Tomihiko Ide, Hajime Niimi, Eishin Yaoita, Yusuke Seino, Yoshihisa Sugimura, Atsushi Suzuki
International Journal of Endocrinology.2019; 2019: 1. CrossRef
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Pragyi Shrestha, Bart van de Sluis, Robin P.F. Dullaart, Jacob van den Born
Cellular Signalling.2019; 55: 53. CrossRef
Understanding the burden of refractory myasthenia gravis
Christiane Schneider-Gold, Tim Hagenacker, Nico Melzer, Tobias Ruck
Therapeutic Advances in Neurological Disorders.2019; 12: 175628641983224. CrossRef
Drug-induced diabetes type 2: In silico study involving class B GPCRs
Dorota Latek, Ewelina Rutkowska, Szymon Niewieczerzal, Judyta Cielecka-Piontek, Arun Shukla
PLOS ONE.2019; 14(1): e0208892. CrossRef
Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study
Toshiyuki Takahashi, Takayuki Okamoto, Yasuyuki Sato, Takeshi Yamazaki, Asako Hayashi, Hayato Aoyagi, Michihiko Ueno, Norio Kobayashi, Kimiaki Uetake, Masanori Nakanishi, Tadashi Ariga
Pediatric Nephrology.2019; 34(1): 87. CrossRef
Management of hyperglycaemia in persons with non-insulin-dependent type 2 diabetes mellitus who are started on systemic glucocorticoid therapy: a systematic review
Milos Tatalovic, Roger Lehmann, Marcus Cheetham, Albina Nowak, Edouard Battegay, Silvana K Rampini
BMJ Open.2019; 9(5): e028914. CrossRef
The effect of diabetes mellitus on in-hospital hyperglycemia, length of stay and survival in patients with brain tumor receiving dexamethasone: A descriptive and comparative analysis
Panteleimon Pantelidis, Parmenion P. Tsitsopoulos, Eleni Pappa, Elpida Theologou, Nikolaos Karanikolas, Christos Drosos, Christos Tsonidis
Clinical Neurology and Neurosurgery.2019; 184: 105450. CrossRef
Impact of glucocorticoid treatment before pregnancy on glucose homeostasis of offspring exposed to glucocorticoid in adult life
Flávia Natividade da Silva, Henver Simionato Brunetta, Maciel Alencar Bruxel, Felipe Azevedo Gomes, Alex Rafacho
Life Sciences.2019; 237: 116913. CrossRef
One week of continuous corticosterone exposure impairs hepatic metabolic flexibility, promotes islet β-cell proliferation, and reduces physical activity in male C57BL/6 J mice
Susan J. Burke, Heidi M. Batdorf, Tai-Yu Huang, Joseph W. Jackson, Katarina A. Jones, Thomas M. Martin, Kristen E. Rohli, Michael D. Karlstad, Tim E. Sparer, David H. Burk, Shawn R. Campagna, Robert C. Noland, Paul L. Soto, J. Jason Collier
The Journal of Steroid Biochemistry and Molecular Biology.2019; 195: 105468. CrossRef
Effect of preadmission glucocorticoid therapy on 30-day mortality in critically ill patients: a retrospective study of a mixed ICU population in a tertiary hospital
Tak Kyu Oh, In-Ae Song, Jae Ho Lee, Cheong Lim, Young-Tae Jeon, Hee-Joon Bae, You Hwan Jo
Annals of Intensive Care.2019;[Epub] CrossRef
Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients
Amy Hiestand, James Flory, Ritika Chitkara
Current Diabetes Reports.2019;[Epub] CrossRef
Corticothérapie prolongée chez une personne âgée et diabète
J.L. Schlienger
Médecine des Maladies Métaboliques.2018; 12(7): 599. CrossRef
Activation of nuclear receptor PXR impairs glucose tolerance and dysregulates GLUT2 expression and subcellular localization in liver
Fatemeh Hassani-Nezhad-Gashti, Jaana Rysä, Outi Kummu, Juha Näpänkangas, Marcin Buler, Mikko Karpale, Janne Hukkanen, Jukka Hakkola
Biochemical Pharmacology.2018; 148: 253. CrossRef
Diabetes Mellitus Secondary to Cushing’s Disease
Mattia Barbot, Filippo Ceccato, Carla Scaroni
Frontiers in Endocrinology.2018;[Epub] CrossRef
MANAGEMENT OF ENDOCRINE DISEASE: Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia
Anjana Radhakutty, Morton G Burt
European Journal of Endocrinology.2018; 179(4): R207. CrossRef
Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: A case-control study
Ala Keyany, Johannes T.H. Nielen, Patrick C. Souverein, Frank de Vries, Bart van den Bemt
Diabetes Research and Clinical Practice.2018; 139: 100. CrossRef
Dominance of the hypothalamus-pituitary-adrenal axis over the renin-angiotensin-aldosterone system is a risk factor for decreased insulin secretion
Makoto Daimon, Aya Kamba, Hiroshi Murakami, Satoru Mizushiri, Sho Osonoi, Kota Matsuki, Eri Sato, Jutaro Tanabe, Shinobu Takayasu, Yuki Matsuhashi, Miyuki Yanagimachi, Ken Terui, Kazunori Kageyama, Itoyo Tokuda, Shizuka Kurauchi, Shigeyuki Nakaji
Scientific Reports.2017;[Epub] CrossRef